Top

Published in:

01-01-2015 | Review

A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia

Authors: J.F. Chen, K. H. Yang, Z.L. Zhang, H.C. Chang, Y. Chen, H. Sowa, S. Gürbüz

Published in: Osteoporosis International | Issue 1/2015

Abstract

This systematic review aimed to examine the evidence for teriparatide in Asia for osteoporosis with a high fracture risk and for exploratory (unapproved) bone-related indications. MEDLINE (1946+), EMBASE (1966+), and ClinicalTrials.gov (2008+) were searched (16 August 2013); all studies of daily subcutaneous teriparatide 20 μg for bone-related conditions from China, Hong Kong, Japan, Republic of Korea, Philippines, Singapore, and Taiwan were included. Evidence on efficacy/safety was retrieved primarily from randomized controlled trials (10 publications) of postmenopausal women from Japan and China. In these studies, teriparatide was well tolerated; subjects had significantly greater increases in lumbar spine bone mineral density (BMD) from baseline compared with placebo, antiresorptive agents, or elcatonin/calcitonin; bone turnover markers increased from baseline and were sustained at elevated levels during teriparatide treatment. Few studies reported fracture risk, pain, or quality of life; one study showed a lower incidence of new-onset vertebral fracture with teriparatide versus antiresorptive agents. Nonrandomized studies (nine publications, one unpublished trial) conducted mainly in Taiwan, Japan, and the Republic of Korea provided supporting data for efficacy. The exploratory (unapproved) use of teriparatide (17 publications) for fracture healing and osteonecrosis of the jaw was described primarily in case reports. The clinical effectiveness of teriparatide for treatment of postmenopausal women with osteoporosis who are at high risk of fracture in Asia is focused primarily on improvements in BMD and tolerability. Recommended additional studies may include assessment of fracture risk and the effect of teriparatide on pain, quality of life, and mortality in Asia.

Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltaev N (1994) The diagnosis of osteoporosis. J Bone Miner Res 9(8):1137–1141. doi:10.1002/jbmr.5650090802 PubMedCrossRef

Albrand G, Munoz F, Sornay-Rendu E, DuBoeuf F, Delmas PD (2003) Independent predictors of all osteoporosis-related fractures in healthy postmenopausal women: the OFELY study. Bone 32(1):78–85PubMedCrossRef

World Health Organization (2004) WHO Scientific Group on the assessment of osteoporosis at primary health care level: summary meeting report. Brussels, Belgium

2009 National Health Statistics. Korea National Health and Nutrition Examination Survey (KNHANESIV-3) (30 August 2012). Available via http://knhanes.cdc.go.kr/. Accessed 12 June 2014

Lin YC, Pan WH (2011) Bone mineral density in adults in Taiwan: results of the nutrition and health survey in Taiwan 2005–2008 (NAHSIT 2005–2008). Asia Pac J Clin Nutr 20(2):283–291PubMed

Wang Y, Tao Y, Hyman ME, Li J, Chen Y (2009) Osteoporosis in China. Osteoporos Int 20(10):1651–1662. doi:10.1007/s00198-009-0925-y PubMedCrossRef

Yoshimura N, Muraki S, Oka H, Mabuchi A, En-Yo Y, Yoshida M, Saika A, Yoshida H, Suzuki T, Yamamoto S, Ishibashi H, Kawaguchi H, Nakamura K, Akune T (2009) Prevalence of knee osteoarthritis, lumbar spondylosis, and osteoporosis in Japanese men and women: the research on osteoarthritis/osteoporosis against disability study. J Bone Miner Metab 27(5):620–628. doi:10.1007/s00774-009-0080-8 PubMedCrossRef

Zhang ZQ, Ho SC, Chen ZQ, Zhang CX, Chen YM (2014) Reference values of bone mineral density and prevalence of osteoporosis in Chinese adults. Osteoporos Int 25(2):497–507. doi:10.1007/s00198-013-2418-2 PubMedCrossRef

Chan DC, Lee YS, Wu YJ, Tsou HH, Chen CT, Hwang JS, Tsai KS, Yang RS (2013) A 12-year ecological study of hip fracture rates among older Taiwanese adults. Calcif Tissue Int 93(5):397–404. doi:10.1007/s00223-013-9759-x PubMedCrossRef

10.

Cooper C, Campion G, Melton LJ 3rd (1992) Hip fractures in the elderly: a world-wide projection. Osteoporos Int 2(6):285–289PubMedCrossRef

11.

Hagino H, Sakamoto K, Harada A, Nakamura T, Mutoh Y, Mori S, Endo N, Nakano T, Itoi E, Kita K, Yamamoto N, Aoyagi K, Yamazaki K (2010) Nationwide one-decade survey of hip fractures in Japan. J Orthop Sci 15(6):737–745. doi:10.1007/s00776-010-1543-4 PubMedCrossRef

12.

Lau EM, Cooper C, Fung H, Lam D, Tsang KK (1999) Hip fracture in Hong Kong over the last decade—a comparison with the UK. J Public Health Med 21(3):249–250PubMedCrossRef

13.

Xia WB, He SL, Xu L, Liu AM, Jiang Y, Li M, Wang O, Xing XP, Sun Y, Cummings SR (2012) Rapidly increasing rates of hip fracture in Beijing, China. J Bone Miner Res 27(1):125–129. doi:10.1002/jbmr.519 PubMedCrossRef

14.

Johnell O, Kanis JA (2004) An estimate of the worldwide prevalence, mortality and disability associated with hip fracture. Osteoporos Int 15(11):897–902. doi:10.1007/s00198-004-1627-0 PubMedCrossRef

15.

Nojiri S, Burge RT, Flynn JA, Foster SA, Sowa H (2013) Osteoporosis and treatments in Japan: management for preventing subsequent fractures. J Bone Miner Metab 31(4):367–380. doi:10.1007/s00774-013-0444-y PubMedCrossRef

16.

Division of Osteoporosis and Bone Mineral Diseases—Chinese Medical Association (2011) Diagnostic and treatment guidelines for primary osteoporosis. Chin J Osteoporosis Bone Miner Res 4(1):2–17

17.

Hwang JS, Chan DC, Chen JF, Cheng TT, Wu CH, Soong YK, Tsai KS, Yang RS (2014) Clinical practice guidelines for the prevention and treatment of osteoporosis in Taiwan: summary. J Bone Miner Metab 32(1):10–16. doi:10.1007/s00774-013-0495-0 PubMedCrossRef

18.

National Osteoporosis Foundation (January 2010) Clinician’s guide to prevention and treatment of osteoporosis. Available via http://www.nof.org/files/nof/public/content/file/344/upload/159.pdf. Accessed 12 June 2014

19.

Orimo H, Nakamura T, Hosoi T, Iki M, Uenishi K, Endo N, Ohta H, Shiraki M, Sugimoto T, Suzuki T, Soen S, Nishizawa Y, Hagino H, Fukunaga M, Fujiwara S (2012) Japanese 2011 guidelines for prevention and treatment of osteoporosis—executive summary. Arch Osteoporos 7(1–2):3–20. doi:10.1007/s11657-012-0109-9 PubMedCentralPubMedCrossRef

20.

Cheung T, Choi T, Chow S, Ho Y, Kan S, Kung W, Lee K, Leung K, Leung Y, Lo S, Sy C, Wong Y, Osteoporosis Society of Hong Kong (2013) The Osteoporosis Society of Hong Kong (OSHK): 2013 OSHK guideline for clinical management of postmenopausal osteoporosis in Hong Kong. Hong Kong Med J 19(Suppl 2):1–40PubMed

21.

Compston JE (2007) Skeletal actions of intermittent parathyroid hormone: effects on bone remodelling and structure. Bone 40(6):1447–1452. doi:10.1016/j.bone.2006.09.008 PubMedCrossRef

22.

Zhang D, Potty A, Vyas P, Lane J (2014) The role of recombinant PTH in human fracture healing: a systematic review. J Orthop Trauma 28(1):58–62. doi:10.1097/BOT.0b013e31828e13fe CrossRef

23.

Kurland ES, Cosman F, McMahon DJ, Rosen CJ, Lindsay R, Bilezikian JP (2000) Parathyroid hormone as a therapy for idiopathic osteoporosis in men: effects on bone mineral density and bone markers. J Clin Endocrinol Metab 85(9):3069–3076PubMed

24.

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY, Hodsman AB, Eriksen EF, Ish-Shalom S, Genant HK, Wang O, Mitlak BH (2001) Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344(19):1434–1441. doi:10.1056/NEJM200105103441904 PubMedCrossRef

25.

Prevrhal S, Krege JH, Chen P, Genant H, Black DM (2009) Teriparatide vertebral fracture risk reduction determined by quantitative and qualitative radiographic assessment. Curr Med Res Opin 25(4):921–928. doi:10.1185/03007990902790993 PubMedCrossRef

26.

Orwoll ES, Scheele WH, Paul S, Adami S, Syversen U, Diez-Perez A, Kaufman JM, Clancy AD, Gaich GA (2003) The effect of teriparatide [human parathyroid hormone (1-34)] therapy on bone density in men with osteoporosis. J Bone Miner Res 18(1):9–17. doi:10.1359/jbmr.2003.18.1.9 PubMedCrossRef

27.

Freemantle N, Cooper C, Diez-Perez A, Gitlin M, Radcliffe H, Shepherd S, Roux C (2013) Results of indirect and mixed treatment comparison of fracture efficacy for osteoporosis treatments: a meta-analysis. Osteoporos Int 24(1):209–217. doi:10.1007/s00198-012-2068-9 PubMedCentralPubMedCrossRef

28.

Han SL, Wan SL (2012) Effect of teriparatide on bone mineral density and fracture in postmenopausal osteoporosis: meta-analysis of randomised controlled trials. Int J Clin Pract 66(2):199–209. doi:10.1111/j.1742-1241.2011.02837.x PubMedCrossRef

29.

Murad MH, Drake MT, Mullan RJ, Mauck KF, Stuart LM, Lane MA, Abu Elnour NO, Erwin PJ, Hazem A, Puhan MA, Li T, Montori VM (2012) Clinical review comparative effectiveness of drug treatments to prevent fragility fractures: a systematic review and network meta-analysis. J Clin Endocrinol Metab 97(6):1871–1880. doi:10.1210/jc.2011-3060 PubMedCrossRef

30.

Shen L, Xie X, Su Y, Luo C, Zhang C, Zeng B (2011) Parathyroid hormone versus bisphosphonate treatment on bone mineral density in osteoporosis therapy: a meta-analysis of randomized controlled trials. PLoS One 6(10):e26267. doi:10.1371/journal.pone.0026267 PubMedCentralPubMedCrossRef

31.

Lei SF, Chen Y, Xiong DH, Li LM, Deng HW (2006) Ethnic difference in osteoporosis-related phenotypes and its potential underlying genetic determination. J Musculoskelet Neuronal Interact 6(1):36–46PubMed

32.

Sanchez-Riera L, Wilson N, Kamalaraj N, Nolla JM, Kok C, Li Y, Macara M, Norman R, Chen JS, Smith EU, Sambrook PN, Hernandez CS, Woolf A, March L (2010) Osteoporosis and fragility fractures. Best Pract Res Clin Rheumatol 24(6):793–810. doi:10.1016/j.berh.2010.10.003 PubMedCrossRef

33.

Chiang TI, Chang IC, Lee HS, Lee H, Huang CH, Cheng YW (2011) Osteopontin regulates anabolic effect in human menopausal osteoporosis with intermittent parathyroid hormone treatment. Osteoporos Int 22(2):577–585PubMedCrossRef

34.

Choe EY, Song JE, Park KH, Seok H, Lee EJ, Lim SK, Rhee Y (2012) Effect of teriparatide on pregnancy and lactation-associated osteoporosis with multiple vertebral fractures. J Bone Miner Metab 30(5):596–601PubMedCrossRef

35.

Dai K, Cai C, Zhang Z, Zhang K, Wang B, He L, Liu B, Xu H, Hu Y, Cao Y, Yu M, Blair L, Luo T (2011) Comparison of the effects of subcutaneous teriparatide and intranasal calcitonin in treating established osteoporosis in Chinese postmenopausal women. Chin J Osteoporos Bone Miner Res 4(1):23–31

36.

Huang HT, Kang L, Huang PJ, Fu YC, Lin SY, Hsieh CH, Chen JC, Cheng YM, Chen CH (2012) Successful teriparatide treatment of atypical fracture after long-term use of alendronate without surgical procedure in a postmenopausal woman: a case report. Menopause 19(12):1360–1363PubMedCrossRef

37.

Hwang JS, Tu ST, Yang TS, Chen JF, Wang CJ, Tsai KS (2006) Teriparatide vs. calcitonin in the treatment of Asian postmenopausal women with established osteoporosis. Osteoporos Int 17(3):373–378PubMedCrossRef

38.

Iwamoto J, Yago K, Sato Y, Matsumoto H (2012) Teriparatide therapy for bisphosphonate-associated osteonecrosis of the jaw in an elderly Japanese woman with severe osteoporosis. Clin Drug Invest 32(8):547–553

39.

Jeon YK, Kim KM, Kim KJ, Kim IJ, Lim SK, Rhee Y (2013) The anabolic effect of teriparatide is undermined by low levels of high-density lipoprotein cholesterol. Calcif Tissue Int:1–10

40.

Kim KM, Park W, Kim HJ, Nam W, Lim SK, Cha IH, Rhee Y (2012) Distinctive role of 6-month teriparatide on advanced bisphosphonate-related osteonecrosis of the jaw (BRONJ); case-control study. Endocr Rev 33(3):OR08–03

41.

Kung AW, Pasion EG, Sofiyan M, Lau EM, Tay BK, Lam KS, Wilawan K, Ongphiphadhanakul B, Thiebaud D (2006) A comparison of teriparatide and calcitonin therapy in postmenopausal Asian women with osteoporosis: a 6-month study. Curr Med Res Opin 22(5):929–937. doi:10.1185/030079906x104768 PubMedCrossRef

42.

Kwon YD, Lee DW, Choi BJ, Lee JW, Kim DY (2012) Short-term teriparatide therapy as an adjunctive modality for bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 23(11):2721–2725PubMedCrossRef

43.

Lee JJ, Cheng SJ, Jeng JH, Chiang CP, Lau HP, Kok SH (2011) Successful treatment of advanced bisphosphonate-related osteonecrosis of the mandible with adjunctive teriparatide therapy. Head Neck 33(9):1366–1371PubMedCrossRef

44.

Lee YK, Ha YC, Koo KH (2012) Teriparatide, a nonsurgical solution for femoral nonunion? A report of three cases. Osteoporos Int 23(12):2897–2900PubMedCrossRef

45.

Li Y, Xuan M, Wang B, Yang J, Zhang H, Zhang XZ, Guo XH, Lu XF, Xue QY, Yang GY, Ji QH, Liu ZM, Li CJ, Wu TF, Sheng ZY, Li PQ, Tong JC (2013) Comparison of parathyroid hormone (1-34) and elcatonin in postmenopausal women with osteoporosis: an 18-month randomized, multicenter controlled trial in China. Chin Med J 126(3):457–463PubMed

46.

Miyauchi A, Matsumoto T, Shigeta H, Tsujimoto M, Thiebaud D, Nakamura T (2008) Effect of teriparatide on bone mineral density and biochemical markers in Japanese women with postmenopausal osteoporosis: a 6-month dose-response study. J Bone Miner Metab 26(6):624–634PubMedCrossRef

47.

Miyauchi A, Matsumoto T, Sugimoto T, Tsujimoto M, Warner MR, Nakamura T (2010) Effects of teriparatide on bone mineral density and bone turnover markers in Japanese subjects with osteoporosis at high risk of fracture in a 24-month clinical study: 12-month, randomized, placebo-controlled, double-blind and 12-month open-label phases. Bone 47(3):493–502PubMedCrossRef

48.

Mokuda S, Sawada N, Matoba K, Yamada A, Onishi M, Okuda Y, Jouyama K, Murata Y, Takasugi K (2012) Serum undercarboxylated osteocalcin level increases with 48 weeks of teriparatide treatment in pre-treated elderly rheumatoid arthritis patients who use anti-resorptive drugs. J Endocrinol Invest 35(9):796–799PubMedCrossRef

49.

Niimi R, Kono T, Nishihara A, Hasegawa M, Matsumine A, Nakamura T, Kono T, Sudo A (2013) An algorithm using the early changes in PINP to predict the future BMD response for patients treated with daily teriparatide. Osteoporos Int:1–8

50.

Oh H, Choi W, Choi H, Kim J, Lim S, Joo I (2010) Bone mineral density and bone turnover markers after one-year teriparatide treatment in Korean postmenopausal women with osteoporosis. Osteoporos Int 21:S183–S184CrossRef

51.

Ohbayashi Y, Miyake M, Sawai F, Minami Y, Iwasaki A, Matsui Y (2013) Adjunct teriparatide therapy with monitoring of bone turnover markers and bone scintigraphy for bisphosphonate-related osteonecrosis of the jaw. Oral Surg Oral Med Oral Pathol Oral Radiol 115(4):e31–37. doi:10.1016/j.oooo.2012.09.006 PubMedCrossRef

52.

Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Ozawa T, Takahashi K, Toyone T (2012) Teriparatide accelerates lumbar posterolateral fusion in women with postmenopausal osteoporosis: prospective study. Spine 37(23):e1464–e1468PubMedCrossRef

53.

Ohtori S, Inoue G, Orita S, Yamauchi K, Eguchi Y, Ochiai N, Kishida S, Kuniyoshi K, Aoki Y, Nakamura J, Ishikawa T, Miyagi M, Kamoda H, Suzuki M, Kubota G, Sakuma Y, Oikawa Y, Inage K, Sainoh T, Takaso M, Toyone T, Takahashi K (2013) Comparison of teriparatide and bisphosphonate treatment to reduce pedicle screw loosening after lumbar spinal fusion surgery in postmenopausal women with osteoporosis from a bone quality perspective. Spine 38(8):e487–e492PubMedCrossRef

54.

Park JH, Kang KC, Shin DE, Koh YG, Son JS, Kim BH (2014) Preventive effects of conservative treatment with short-term teriparatide on the progression of vertebral body collapse after osteoporotic vertebral compression fracture. Osteoporos Int 25(2):613–618. doi:10.1007/s00198-013-2458-7 PubMedCrossRef

55.

Song KE, Min YK, Lee JK, Lee KB, Joo HJ, Kwack KS, Chung YS (2008) A probable case of oral bisphosphonate-associated osteonecrosis of the jaw and recovery with parathyroid hormone treatment. Curr Ther Res Clin Exp 69(4):356–362PubMedCentralPubMedCrossRef

56.

Su CH, Tu PH, Yang TC, Tseng YY (2013) Comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. J Spinal Disord Tech 26(4):200–206PubMedCrossRef

57.

Tamai K, Takamatsu K, Kazuki K (2013) Successful treatment of nonunion with teriparatide after failed ankle arthrodesis for Charcot arthropathy. Osteoporos Int 24(10):2729–2732. doi:10.1007/s00198-013-2367-9 PubMedCentralPubMedCrossRef

58.

Tseng YY, Su CH, Lui TN, Yeh YS, Yeh SH (2012) Prospective comparison of the therapeutic effect of teriparatide with that of combined vertebroplasty with antiresorptive agents for the treatment of new-onset adjacent vertebral compression fracture after percutaneous vertebroplasty. Osteoporos Int 23(5):1613–1622PubMedCentralPubMedCrossRef

59.

Tsujimoto M, Chen P, Miyauchi A, Sowa H, Krege JH (2011) PINP as an aid for monitoring patients treated with teriparatide. Bone 48(4):798–803PubMedCrossRef

60.

Tsujimoto M, Uenaka K, Iwata A, Higashiuchi Y, Sowa H (2012) Effects of teriparatide in Japanese and non-Japanese populations: bridging findings on pharmacokinetics and efficacy. J Bone Miner Metab 30(3):326–337PubMedCrossRef

61.

Tu PH, Liu ZH, Lee ST, Chen JF (2012) Treatment of repeated and multiple new-onset osteoporotic vertebral compression fractures with teriparatide. J Clin Neurosci 19(4):532–535PubMedCrossRef

62.

Wu C, Yu C (2010) Salvaged effect of teriparatide on impending failed femoral neck facture surgery. Osteoporos Int 21:S384

63.

Wu CC, Wei JCC, Hsieh CP, Yu CT (2012) Enhanced healing of sacral and pubic insufficiency fractures by teriparatide. J Rheumatol 39(6):1306–1307PubMedCrossRef

64.

Yamamoto T, Tsujimoto M, Hamaya E, Sowa H (2013) Assessing the effect of baseline status of serum bone turnover markers and vitamin D levels on efficacy of teriparatide 20 μg/day administered subcutaneously in Japanese patients with osteoporosis. J Bone Miner Metab 31(2):199–205. doi:10.1007/s00774-012-0403-z PubMedCrossRef

65.

Yoshiga D, Yamashita Y, Nakamichi I, Tanaka T, Yamauchi K, Yamamoto N, Nogami S, Kaneuji T, Mitsugi S, Sakurai T, Kiyomiya H, Tominaga K, Morimoto Y, Takahashi T (2013) Weekly teriparatide injections successfully treated advanced bisphosphonate-related osteonecrosis of the jaws. Osteoporos Int 24(8):2365–2369PubMedCentralPubMedCrossRef

66.

Yu CT (2011) Enhanced hip fractures union with teriparatide. Osteoporos Int 22:S134

67.

Yu CT, Wu JK, Chang CC, Chen CL, Wei JCC (2008) Early callus formation in human hip fracture treated with internal fixation and teriparatide. J Rheumatol 35(10):2082PubMed

68.

Zhang L, Li L, Yang M, Xu K, Boden G, Yang G (2013) The rhPTH treatment elevates plasma secreted protein acidic and rich in cysteine levels in patients with osteoporosis. Osteoporos Int 24(3):1107–1112. doi:10.1007/s00198-012-1956-3 PubMedCrossRef

69.

Zhang L, Yang M, Liu D, Guo C, Li L, Yang G (2012) The rhPTH (1-34), but not elcatonin, increases bone anabolic efficacy in postmenopausal women with osteoporosis. Exp Clin Endocrinol Diabetes 120(6):361–366PubMedCrossRef

70.

Zhang XZ, Wang B, Yang J, Xuan M, Song LG, Li H, Guo XH, Lu XF, Xue QY, Yang GY, Ji QH, Shen J, Liu ZM, Li CJ, Wu TF, Tong XC, Jia Y (2009) A randomized, multicenter controlled trial to compare the efficacy of recombinant human parathyroid hormone (1-34) with elcatonin in postmenopausal women with osteoporosis in China. Chin Med J 122(24):2933–2938PubMed

71.

Zhu W, Yang ML, Yang GY, Boden G, Li L (2012) Changes in serum runt-related transcription factor 2 levels after a 6-month treatment with recombinant human parathyroid hormone in patients with osteoporosis. J Endocrinol Invest 35(6):602–606. doi:10.3275/8110 PubMed

72.

A study of teriparatide in Japanese osteoporosis patients [NCT01430104] (7 January 2013) US National Institutes of Health. www.clinicaltrials.gov. Accessed 12 June 2014

73.

Phase 3 trial of teriparatide in Japan [NCT00433160] (14 September 2010) US National Institutes of Health. www.clinicaltrials.gov. Accessed 12 June 2014

74.

A study for patients with osteoporosis [NCT00414973] (22 October 2009) US National Institutes of Health. www.clinicaltrials.gov. Accessed 12 June 2014

75.

European Medicines Agency (September 1998) ICH Topic E 5 (R1) Ethnic factors in the acceptability of foreign clinical data (CPMP/ICH/289/95). Available via http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002842.pdf. Accessed 12 June 2014

76.

Borggrefe J, Graeff C, Nickelsen TN, Marin F, Gluer CC (2010) Quantitative computed tomographic assessment of the effects of 24 months of teriparatide treatment on 3D femoral neck bone distribution, geometry, and bone strength: results from the EUROFORS study. J Bone Miner Res 25(3):472–481. doi:10.1359/jbmr.090820 PubMedCrossRef

77.

Graeff C, Chevalier Y, Charlebois M, Varga P, Pahr D, Nickelsen TN, Morlock MM, Gluer CC, Zysset PK (2009) Improvements in vertebral body strength under teriparatide treatment assessed in vivo by finite element analysis: results from the EUROFORS study. J Bone Miner Res 24(10):1672–1680. doi:10.1359/jbmr.090416 PubMedCrossRef

78.

Graeff C, Timm W, Nickelsen TN, Farrerons J, Marin F, Barker C, Gluer CC, Eurofors High Resolution Computed Tomography Substudy Group (2007) Monitoring teriparatide-associated changes in vertebral microstructure by high-resolution CT in vivo: results from the EUROFORS study. J Bone Miner Res 22(9):1426–1433. doi:10.1359/jbmr.070603 PubMedCrossRef

79.

Nakamura T, Tsujimoto M, Hamaya E, Sowa H, Chen P (2012) Consistency of fracture risk reduction in Japanese and Caucasian osteoporosis patients treated with teriparatide: a meta-analysis. J Bone Miner Metab 30(3):321–325. doi:10.1007/s00774-011-0313-5 PubMedCrossRef

80.

Fahrleitner-Pammer A, Langdahl BL, Marin F, Jakob F, Karras D, Barrett A, Ljunggren O, Walsh JB, Rajzbaum G, Barker C, Lems WF (2011) Fracture rate and back pain during and after discontinuation of teriparatide: 36-month data from the European Forsteo Observational Study (EFOS). Osteoporos Int 22(10):2709–2719. doi:10.1007/s00198-010-1498-5 PubMedCentralPubMedCrossRef

81.

Ljunggren O, Barrett A, Stoykov I, Langdahl BL, Lems WF, Walsh JB, Fahrleitner-Pammer A, Rajzbaum G, Jakob F, Karras D, Marin F (2013) Effective osteoporosis treatment with teriparatide is associated with enhanced quality of life in postmenopausal women with osteoporosis: the European Forsteo Observational Study. BMC Musculoskelet Disord 14:251. doi:10.1186/1471-2474-14-251 PubMedCentralPubMedCrossRef

82.

Downey TW, Foltz SH, Boccuzzi SJ, Omar MA, Kahler KH (2006) Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting. South Med J 99(6):570–575PubMedCrossRef

83.

Tanaka I, Sato M, Sugihara T, Faries D, Nojiri S, Graham-Clarke P, Flynn J, Burge R (2013) Adherence and persistence with once-daily teriparatide in Japan: a retrospective, prescription database, cohort study. J Osteoporos. doi:10.1155/2013/654218 PubMedCentralPubMed

84.

Foster SA, Foley KA, Meadows ES, Johnston JA, Wang SS, Pohl GM, Long SR (2011) Adherence and persistence with teriparatide among patients with commercial, Medicare, and Medicaid insurance. Osteoporos Int 22(2):551–557. doi:10.1007/s00198-010-1297-z PubMedCrossRef

85.

Yu S, Burge RT, Foster SA, Gelwicks S, Meadows ES (2012) The impact of teriparatide adherence and persistence on fracture outcomes. Osteoporos Int 23(3):1103–1113. doi:10.1007/s00198-011-1843-3 PubMedCrossRef

86.

Kothawala P, Badamgarav E, Ryu S, Miller RM, Halbert RJ (2007) Systematic review and meta-analysis of real-world adherence to drug therapy for osteoporosis. Mayo Clin Proc 82(12):1493–1501. doi:10.1016/S0025-6196(11)61093-8 PubMedCrossRef

87.

Center for Drug Evaluation and Research (27 July 2001). Available via http://www.fda.gov/ohrms/dockets/ac/01/transcripts/3761t2_01.pdf. Accessed 12 June 2014

88.

Vahle JL, Sato M, Long GG, Young JK, Francis PC, Engelhardt JA, Westmore MS, Linda Y, Nold JB (2002) Skeletal changes in rats given daily subcutaneous injections of recombinant human parathyroid hormone (1-34) for 2 years and relevance to human safety. Toxicol Pathol 30(3):312–321PubMedCrossRef

89.

Andrews EB, Gilsenan AW, Midkiff K, Sherrill B, Wu Y, Mann BH, Masica D (2012) The US postmarketing surveillance study of adult osteosarcoma and teriparatide: study design and findings from the first 7 years. J Bone Miner Res 27(12):2429–2437. doi:10.1002/jbmr.1768 PubMedCentralPubMedCrossRef

90.

Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA (2010) Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21(6):1041–1045. doi:10.1007/s00198-009-1004-0 PubMedCrossRef

91.

Harper KD, Krege JH, Marcus R, Mitlak BH (2007) Osteosarcoma and teriparatide? J Bone Miner Res 22(2):334. doi:10.1359/jbmr.061111 PubMedCrossRef

92.

Andreassen TT, Fledelius C, Ejersted C, Oxlund H (2001) Increases in callus formation and mechanical strength of healing fractures in old rats treated with parathyroid hormone. Acta Orthop Scand 72(3):304–307. doi:10.1080/00016470152846673 PubMedCrossRef

93.

Barros SP, Silva MA, Somerman MJ, Nociti FH Jr (2003) Parathyroid hormone protects against periodontitis-associated bone loss. J Dent Res 82(10):791–795PubMedCrossRef

94.

Chalidis B, Tzioupis C, Tsiridis E, Giannoudis PV (2007) Enhancement of fracture healing with parathyroid hormone: preclinical studies and potential clinical applications. Expert Opin Investig Drugs 16(4):441–449. doi:10.1517/13543784.16.4.441 PubMedCrossRef

95.

Aspenberg P, Genant HK, Johansson T, Nino AJ, See K, Krohn K, Garcia-Hernandez PA, Recknor CP, Einhorn TA, Dalsky GP, Mitlak BH, Fierlinger A, Lakshmanan MC (2010) Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. J Bone Miner Res 25(2):404–414. doi:10.1359/jbmr.090731 PubMedCrossRef

96.

Bashutski JD, Eber RM, Kinney JS, Benavides E, Maitra S, Braun TM, Giannobile WV, McCauley LK (2010) Teriparatide and osseous regeneration in the oral cavity. N Engl J Med 363(25):2396–2405. doi:10.1056/NEJMoa1005361 PubMedCrossRef

97.

Song H, Kim S, Lee J, Yang K (2012) Intermittent parathyroid hormone treatment for stimulation of callus formation in elderly patients [in Korean]. J Korean Fract Soc 25(4):295–299CrossRef

Title: A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia
Authors: J.F. Chen
K. H. Yang
Z.L. Zhang
H.C. Chang
Y. Chen
H. Sowa
S. Gürbüz
Publication date: 01-01-2015
Publisher: Springer London
Published in: Osteoporosis International / Issue 1/2015
Print ISSN: 0937-941X
Electronic ISSN: 1433-2965
DOI: https://doi.org/10.1007/s00198-014-2838-7

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

A systematic review on the use of daily subcutaneous administration of teriparatide for treatment of patients with osteoporosis at high risk for fracture in Asia

Abstract

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2015

Polymorphisms in genes in the RANKL/RANK/OPG pathway are associated with bone mineral density at different skeletal sites in post-menopausal women

Sex- and age-specific associations between income and incident major osteoporotic fractures in Canadian men and women: a population-based analysis

Single and combined effect of high-frequency loading and bisphosphonate treatment on the bone micro-architecture of ovariectomized rats

Nasal salmon calcitonin blunts bone microstructure alterations in healthy postmenopausal women

Calcifediol versus vitamin D3 effects on gait speed and trunk sway in young postmenopausal women: a double-blind randomized controlled trial

Evidence of degraded BMD and geometry at the proximal femora in male patients with alcoholic liver cirrhosis